Summary
In patients with atrial fibrillation, apixaban is superior to warfarin in preventing stroke or systemic embolism, causes less bleeding, and results in lower mortality according to primary results from the Apixaban for Reduction In STrOke and other ThromboemboLic Events in atrial fibrillation [ARISTOTLE; NCT00412984] trial.
- Cardiology Clinical Trials
- Arrhythmias
- Cerebrovascular Disease
- © 2011 MD Conference Express
Tools
Apixaban Superior to Warfarin for Prevention of SSE in Patients with AF: Results from ARISTOTLE
Permalink:
Table of contents
Cited By...
- No citing articles found.